drugset / Trial / NCT07239596
Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma
Timeline
- Start
- 2026-01-06
- Primary completion
- 2030-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | HRS-10516 | Unknown | — | — |
| Subject | HS-10516 | Unknown | — | — |
| Subject | SHR-8068 | Monoclonal antibody | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |